Author

A. Abdulnabi

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access 2026

In silico evaluation of binding interactions and ADME properties of new 1, 2, 3-triazole derivatives of benzimidazole as antibacterial agents

Purpose: To predict the antibacterial effects of 1, 2, 3-triazole derivatives of benzimidazole (designated 5A, 5B, and 5C) against four different bacterial species, i.e., Bacillus subtilis, Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae.Methods: The ADME and pharmacokinetic properties of the designed...

A. Abdulnabi, Kanar M. Alawad, Jessica Hanna et al. · Tropical Journal of Pharmace... · 0 citations

Open access Sep 2026

Computational Prioritization of Novel Nabumetone-Derived Heterocycles as Potential Cyclooxygenase-2 Inhibitors

Purpose: To prioritize fifteen novel nabumetone-derived heterocycles as potential cyclooxygenase-2 inhibitors using an integrated in silico workflow. Methods: Compounds N1-N15 were evaluated by molecular docking against meloxicam-bound murine cyclooxygenase-2 (PDB ID: 4M11) using MOE 2019. The protocol was validated by...

A. Abdulnabi, Shireen Nadhem Saleh · International Journal of Bio... · 0 citations

Review Open access Sep 2026

Green-By-Design Pharmaceuticals: from Human Admet to Environmental Safety in AI-Enabled Sustainable Drug Discovery

Objectives to analyze how the concept of pharmaceutical sustainability could be taken further into the upstream processes of candidate selection to combine human ADMET, synthetic efficiency, environmental fate, ecotoxicity, biodegradability and AI without affecting therapeutic performance. This is a critical narrative...

Shireen Nadhem Saleh, A. Abdulnabi · American Journal of Biomedic... · 0 citations